中文

News & Events

dMed raises nearly US$50 million in Series B financing to strengthen and expand its clinical operatio...2019-10-17

Shanghai, October 16, 2019 ---- dMed Biopharmaceutical Co., Ltd. recently announced completion of a nearly US$50 million Series B financing, led by Vivo Capital and joined by Legend Capital, Qiming Ven...

Read More

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Devic...2019-06-26

SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capital...

Read More

dMed Biopharmaceutical announced the opening of its US Regulatory Affairs office in Washington DC2019-06-24

WASHINGTON, June 19, 2019 /PRNewswire/ -- Since the China launch earlier this year of an immuno-oncology drug at one-third the price of Merck's Keytruda, there has been a wave of applications for affor...

Read More

HOW CHINA IS CHANGING THE CLINICAL DEVELOPMENT LANDSCAPE2019-06-24

In less than 24 months, China has radically altered the global clinical development landscape, creating new pathways to commercialization that alter the traditional drug development paradigm.

Read More

dMed Forum in BioBay2019-03-28

dMed Forum was held successfully on March 20th in Suzhou BioBay, co-sponsored by dMed Biopharmaceutical Co., Ltd. & Suzhou Industry Park Pharmaceutical Association (SIPPA: http://www.sippa.org.cn/ ).

Read More

Lingshi Tan – Founder, Chairman and CEO, dMed, China2019-03-18

Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed……

Read More

Interview with Dr. Lingshi Tan by Pharmaceutical Executive (Pharma Exec)—— Drug Regulatory Reform in...2019-03-05

In recent years, the regulatory environment for drugs has undergone tremendous changes in China – from rapid developments in the regulatory system to collaborating with more advanced regulatory systems...

Read More

Conference Report ——Training Course of Population Pharmacokinetics & Phase I PK/PD Clinical Trial2019-02-18

From December 26-27, 2018, the population pharmacokinetics (pop-PK) and Phase I of PK/PD clinical trial training courses were successfully completed in Shanghai

Read More

China:
298 Xiangke Road, 3/F, 301-305, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201210, China
Tel: +86 21 5090 0085 Fax: +86 21 6875 5515
US:
261 Madison Avenue, 24th fl. New York, NY 10016 US
Phone: +1-212-681-2100
沪ICP备16041651号 Copyright © 2016 dMed All Rights Reserved
沪公网安备 31011502005403号